– USA, MA – Repligen Corporation (NASDAQ: RGEN) today announced the appointment of Dr. Konstantin Konstantinov (Ph.D.) to its Board of Directors, bringing nearly 30 years of relevant experience, including his current position as CTO at Codiak BioSciences, where he previously served for six years as EVP, Manufacturing & Process Sciences.
“We are delighted to welcome Dr. Konstantinov to our board. His professional achievements speak to his technical leadership capabilities. These include his pioneering efforts to advance continuous manufacturing along with his bioprocessing domain expertise that spans multiple modalities – all of significant relevance to Repligen and the markets we serve,” said Board Chair, Karen Dawes.
Tony Hunt, President, and CEO added, “Having worked with Konstantin over the last six years on Repligen’s Scientific Advisory Board, it’s clear that his knowledge of our industry and the bioprocessing trends occurring with new biotherapeutic modalities will be a great asset to our Board and the company. We are thrilled to have Konstantin on our Board as we continue on our journey to transform the bioprocessing industry as an innovation leader.”
About Dr. Konstantin Konstantinov
Dr. Konstantinov has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, gene therapy vectors, and exosomes. Over the past decade, he has pioneered the development of integrated continuous biomanufacturing, which is becoming a strategic technological trend in the bioprocessing industry.
Dr. Konstantinov’s involvement with emerging modalities and continuous manufacturing stems from a long career in the development and commercialization of biologic drugs. Before Codiak BioSciences, Dr. Konstantinov was with Genzyme for nine years, where he was named VP overseeing late-stage bioprocess and technology development. Before Genzyme, he was with Bayer Healthcare for 14 years, in various roles of growing responsibility leading to his role as Head of Process Science.
Dr. Konstantinov earned his Ph.D. from Osaka University, with a focus on Biochemical Engineering, after receiving his B.Sc. and M.Sc. from the Technical University of Sofia, Bulgaria.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey, and New York), and outside of the U.S., we have sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information: https://www.repligen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
